PWRM, ACEL and ARNA Three Medical Research Companies Working To Cure Disease.
Stock-PR Reporting
FREE Daily Stock Alerts From Stock-PR.com
________________________________________
Power3 Medical’s (PWRM.OB) mission is to discover new protein biomarkers with clinical and economic utility and use them to develop novel commercial screening and diagnostic tests that benefit clinicians, patients and families by enabling earlier disease detection and treatment.
The Company conducts research and discovery programs and diagnostic development activities designed to provide our customers, patients and physicians alike, with the ability to be better prepared to address a devastating disease life cycle. Power3 will enable clinicians to diagnose earlier, provide therapy earlier and monitor the disease earlier with greater accuracy. By achieving this, patients and their families can be treated for, cope with, and recover from the effects of the disease they possess.
Power3’s emphasis as a pioneering biotechnology discovery and development company has enabled them to leverage their proprietary clinical proteomic processes to begin the development of tools for diagnosis, prognosis, early detection and drug therapies to address the needs in several types of cancers, metabolic syndrome, cardiovascular, and neurodegenerative and neuromuscular diseases such as ALS (Lou Gehrig’s Disease).
Proteomics is the study and analysis of proteins, the fundamental building blocks of the human body. By studying these proteins, scientists can understand more fully the functioning of a healthy body and identify the proteins associated with specific diseases.
Proteins are not only the building blocks for life; in them, evidence can be found for serious diseases such as cancer, Alzheimer’s, or AIDS. The latter can occur if proteins are falsely structured, unnaturally accumulate, or do not exist.
For on-target treatment with new medicines we need to know and compare the exact structure of the diseased-related proteins and the healthy-related proteins. Only if we can specify the precise differences between diseased-related and the healthy-related proteins can we develop new diagnostic tests and drugs that home in on the changed protein structures and destroy them.
This is the starting point for Power3 Medical. The company uses technologies, know-how and proprietary techniques to identify which proteins exist in a specific type of cell, ascertain how they interact, and change in the course of a disease. Power3 focuses on protein-based biomarkers, which are simply proteins that are significant in the diagnosis, monitoring or treatment of disease.
Tamir Biotechnology, Inc. (OTCBB:ACEL) (formerly known as Alfacell Corporation), a biopharmaceutical company focused on the discovery, development, and commercialization of novel ribonuclease (RNase) therapeutics for cancer and virology, today announced that Tommy G. Thompson, former Secretary of the U.S. Department of Health and Human Services and four-term Governor of Wisconsin, has rejoined the company as a Special Advisor to Chief Executive Officer Charles Muniz and will also be the Chairman of its Oncology and Anti-Viral Business Development Advisory Committee.
Secretary Thompson previously was a Special Advisor to the company, but in 2008 he took a leave of absence from the company for personal reasons. Under his expanded duties and responsibilities, Secretary Thompson will chair the newly-created Oncology and Anti-Viral Business Development Committee which will include members of the Company’s senior management team and Board of Directors. The committee will focus on advancement and strategic positioning of the Company’s compounds in the areas of oncology and virology.
“I am extremely pleased to serve in my expanded roles with Tamir, a company with a deep commitment to developing potential breakthroughs in the treatment of cancer and virology,” stated Thompson. “I am delighted with the company’s prospects in further development of its technology platform in the areas of oncology and virology. Recent test results by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI) confirm Tamir’s role as a global leader in ribonuclease-based drug therapies in oncology as well as virology. These results have the potential to provide new therapies for those patients who suffer from these deadly diseases,” stated Thompson.
“It is a privilege to have a preeminent authority on issues involving healthcare like Secretary Thompson on our team. He has dedicated his professional life to public service and is a leading advocate for the health and welfare of all Americans. Additionally, he is committed to finding drugs that can eradicate viral diseases inflicted on those individuals less fortunate in developing countries throughout the world. It is an honor to have Secretary Thompson, our nation’s greatest ambassador on healthcare, biodefense preparedness, and Neglected Infectious Diseases as Special Advisor to my office. Under his direction, Secretary Thompson will be providing executive leadership, organizational direction, and guidance for further research and development of our compounds in government, academia, and industry,” stated Charles Muniz, Chief Executive Officer of Tamir.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. recently announced that results from the two-year BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial will be published in the July 15, 2010, issue of the New England Journal of Medicine. The data presented in the article show that lorcaserin used in conjunction with behavioral modification caused significantly greater weight loss and improved maintenance of weight loss compared to placebo. Lorcaserin also improved values for biomarkers that may be predictive of future cardiovascular events, including lipid levels, insulin resistance, levels of inflammatory markers and blood pressure.
“There is a significant and growing need for effective treatment options that can help patients reduce their weight in a well-tolerated and safe manner,” said Steven R. Smith, M.D., Scientific Director of the Florida Hospital Translational Research Institute for Metabolism and Diabetes. “Lorcaserin patients who completed Year 1 of the BLOOM trial lost an average of 8.2% of their baseline weight and improved their cardiovascular risk factors.”
“We have reached another major milestone for Arena with publication of the BLOOM results in the New England Journal of Medicine,” said Jack Lief, Arena’s President and Chief Executive Officer. “We look forward to continued execution of our plans for lorcaserin and interaction with the FDA as it conducts its review of the NDA.”
At the end of Year 1 of the BLOOM trial, using Intent-to-Treat with Last Observation Carried Forward analysis (ITT-LOCF), the proportion of patients achieving at least 5% body weight loss in the lorcaserin group (47.5%) was more than twice that achieved by the placebo group (20.3%). Nearly three times as many patients achieved at least 10% weight loss in the lorcaserin group (22.6%) than in the placebo group (7.7%). Lorcaserin patients who completed the first year of the trial according to the protocol lost an average of 8.2% of their baseline weight, or approximately 18 pounds, at the end of Year 1 as compared to approximately 7 pounds in the placebo group. In Year 2, patients who continued to take lorcaserin were significantly better able to maintain their Year 1 weight loss than those who were switched to placebo.
In Year 1, lorcaserin caused significant decreases in waist circumference, BMI, glycemic parameters, high-sensitivity C-reactive protein, and fibrinogen levels compared to placebo. Total cholesterol, LDL cholesterol and triglyceride levels at Year 1 were significantly lower in the lorcaserin group than in the placebo group. Lorcaserin did not increase heart rate or blood pressure; rather, heart rate, systolic blood pressure and diastolic blood pressure decreased slightly but significantly with lorcaserin treatment compared to placebo. Quality of life, measured by the Impact of Weight on Quality of Life-Lite questionnaire, improved in both treatment groups, with a greater improvement in the lorcaserin group than in the placebo group.
At the end of Year 1, 55.4% of patients in the lorcaserin group and 45.1% of patients in the placebo group remained enrolled in the study, and 7.1% and 6.7% of patients, respectively, discontinued the study due to an adverse event. Among the most frequent adverse events reported with lorcaserin were headache (18.0% vs. 11.0%, lorcaserin vs. placebo); dizziness (8.2% vs. 3.8%); and nausea (7.5% vs. 5.4%). The rates of serious adverse events were similar in both treatment groups. The rates of depression and the incidence of anxiety and suicidal thoughts were low in both treatment groups. Lorcaserin caused no significant increase compared to placebo in the incidence of new cardiac valvulopathy.
Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________
Be Sure To Visit stock-pr.ning.com
********************************
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.
